John Dwyer

John R. Dwyer, Jr. is the President of the Global Alzheimer’s Platform Foundation (GAP). GAP is a patient centric non-profit organization dedicated to the mission of reducing the time and cost while improving the quality and diversity of AD and other CNS therapeutic clinical studies. Over the last 4 years, in collaboration with our network of many of the leading private and public CNS clinical trial sites in North American, GAP-Net, GAP has or is conducting a dozen Phase 2 or 3 therapeutic studies in AD or PD. These “GAP-enabled” trials have consistently recruited and enrolled 30-50% faster than the industry averages.

In the last two years, GAP has also become a leader in the biomarker and data analytics field with its launching of Bio-Hermes, the largest comparison study of many of the leading blood plasma and digital cognitive tests relative to Beta-Amyloid PET in the AD field today (n=1,000). It is also the most diverse with over 20% of the participants coming from traditionally underrepresented communities. GAP recently announced the launch of its second biomarker study, Aphelia (n=~1,600) which will be transatlantic, as well as 5 GAP-enabled trials focusing on enhanced participation of underrepresented populations in these trials. All of GAP’s data and inventory of samples will be the subject of a multi-modal analytical effort including AI/machine learning based in silico modeling to improve clinical trial design and new target development.

Prior to GAP, John served as the co-founder and Chairman of Telcare, Inc. (Phillips Medesi), a high technology manufacturer of the first wirelessly enabled blood glucose meter system empowering patients with diabetes to better manage their disease.

Mr. Dwyer first became a CEO at the age of 30. In the following years, he has held “C” level positions in six emerging growth companies in the healthcare industry. His past assignments have included serving as CEO of e-Medex, Inc., which merged with Active Health Management (Aetna) to become the leading provider of population health management services. He was also a co-founder and Chairman of CodeRyte, Inc., a venture-backed seller of medical billing software using AI/natural language processing to generate billing codes. CodeRyte was purchased by 3M in 2012.

Mr. Dwyer co-founded Us Against Alzheimer’s, a patient advocacy group focused on changing the way the country addresses the threat posed by Alzheimer’s. He also co-founded the first political action committee focused on a specific disease, the Alzheimer’s Action PAC.

Mr. Dwyer is frequently interviewed on regulatory and patient related issues in the Alzheimer’s and CNS space more broadly. He also regularly speaks on health information issues and the business risks associated with the regulatory and payer process. Mr. Dwyer is a graduate of Marquette University and the Cornell Law School.

Alternative Option 1
In the last two years, GAP has also become a leader in the biomarker and data analytics field with its launching of Bio-Hermes, the largest comparison study of many of the leading blood plasma and digital cognitive tests relative to Beta-Amyloid PET in the AD field today (n=1,000). It is also the most diverse with over 20% of the participants coming from traditionally underrepresented communities. Joining Bio-Hermes, GAP launched its second biomarker study, Aphelia (n=~1,600) which will be transatlantic. All of GAP’s data and inventory of samples will be the subject of a multi-modal analytical effort including AI/machine learning based in silico modeling to improve clinical trial design and new target development.

In addition to new GAP-sponsored studies, GAP is established itself as a leader in addressing health disparities by improving research participation by those who have been traditionally underrepresented. Currently, GAP is engaged in 5 GAP-enabled trials focusing on enhanced participation of people from traditionally underrepresented communities in research. GAP’s commitment to inclusive research opportunities is proven and desired.

Alternative Option 2
In the last two years, GAP has also become a leader in the biomarker and data analytics field with its launching of Bio-Hermes, the largest comparison study of many of the leading blood plasma and digital cognitive tests relative to Beta-Amyloid PET in the AD field today (n=1,000). It is also the most diverse with over 20% of the participants coming from traditionally underrepresented communities.

GAP recently announced its involvement in 5 GAP-enabled trials focusing on improving participation of volunteers from traditionally underrepresented communities, as well as the launch of its second biomarker study, Aphelia (n=~1,600) which will be transatlantic. All of GAP’s data and inventory of samples from Bio-Hermes and Apheleia will be the subject of a multi-modal analytical effort including AI/machine learning based in silico modeling to improve clinical trial design and new target development.